Restatement of Quarterly Financial Information - Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Total revenue	$ 294,208	$ 317,001	$ 269,697	$ 263,258	$ 195,100	$ 227,117	$ 175,638	$ 176,058	$ 1,144,163	$ 773,915	$ 687,180
Expenses	281,628	266,910	254,315	237,047	192,852	173,957	154,650	154,277	1,039,898	675,736	606,677
Income (loss) from operations	12,580	50,091	15,382	26,211	2,248	53,160	20,988	21,781	104,265	98,179	80,503
Net income	(883)	23,897	11,277	11,450	(18,152)	(5,229)	56,269	13,167	45,741	46,055	122,083
Net income attributable to ApolloMed	$ (3,728)	$ 23,185	$ 11,950	$ 13,764	$ 12,279	$ 34,404	$ 10,088	$ 12,152	$ 45,171	$ 68,923	$ 37,688
Earnings per share - basic attributable to common stock (in dollars per share)	$ (0.08)	$ 0.52	$ 0.27	$ 0.31	$ 0.28	$ 0.77	$ 0.23	$ 0.29	$ 1.00	$ 1.57	$ 1.03
Earnings per share - diluted attributable to common stock (in dollars per share)	$ (0.08)	$ 0.50	$ 0.26	$ 0.30	$ 0.27	$ 0.74	$ 0.22	$ 0.28	$ 0.99	$ 1.52	$ 1.01